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Abstract
Background: The diagnosis and monitoring of Attention deficit hyperactivity disorder (ADHD) typically relies on
subjective reports and observations. Objective continuous performance tests (CPTs) have been incorporated into
some services to support clinical decision making. However, the feasibility and acceptability of adding such a test
into routine practice is unknown. The study aimed to investigate the feasibility and acceptability of adding an
objective computerised test to the routine assessment and monitoring of attention deficit hyperactivity disorder
(ADHD).
Methods: Semi-structured interviews were conducted with clinicians (n = 10) and families (parents/young people,
n = 20) who participated in a randomised controlled trial. Additionally, the same clinicians (n = 10) and families
(n = 76) completed a survey assessing their experience of the QbTest. The study took place in child and adolescent
mental health and community paediatric clinics across the UK. Interview transcripts were thematically analysed.
Results: Interviewed clinicians and families valued the QbTest for providing an objective, valid assessment of
symptoms. The QbTest was noted to facilitate communication between clinicians, families and schools. However,
whereas clinicians were more unanimous on the usefulness of the QbTest, survey findings showed that, although
the majority of families found the test useful, less than half felt the QbTest helped them understand the clinician’s
decision making around diagnosis and medication. The QbTest was seen as a potentially valuable tool to use early
in the assessment process to streamline the care pathway. Although clinicians were conscious of the additional
costs, these could be offset by reductions in time to diagnosis and the delivery of the test by a Healthcare
Assistant.
Conclusions: The findings indicate the QbTest is an acceptable and feasible tool to implement in routine clinical
settings. Clinicians should be mindful to discuss the QbTest results with families to enable their understanding and
engagement with the process. Further findings from definitive trials are required to understand the cost/benefit;
however, the findings from this study support the feasibility and acceptability of integrating QbTest in the ADHD
care pathway.
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Background
Attention deficit hyperactivity disorder (ADHD) af-
fects approximately 4–8% of school-aged children [1]
and is characterised by symptoms of inattention, im-
pulsivity and hyperactivity that is inappropriate for
the person’s age. The assessment of ADHD typically
relies on the clinician’s judgment which is supple-
mented by the integration of parent, teacher and,
where age-appropriate, young person reports. These
reports can be contradictory, incomplete and are
often not returned in a timely manner, leading to
delays in diagnostic decision making [2, 3]. The as-
sessment of ADHD is further complicated by a high
co-occurrence with other disorders, making a differ-
ential diagnosis complicated and often resulting in
multiple clinic visits to obtain an accurate diagnosis
[3] and substantial cost to the health services [4].
One approach to improving assessment in ADHD is to
supplement clinical judgement with computerised tests
completed by the child as these provide a more objective
measure of attention, impulsivity and activity [2, 5, 6].
Although CPTs should not be used as a stand-alone tool
for assessment, they can be integrated with other
sources of information, such as parent/teacher reports
and clinical opinion to reach a diagnostic decision. One
CPT, ‘QbTest’ (QbTech Ltd, www.qbtech.com) is a com-
mercially available measure of ADHD symptoms ap-
proved by the FDA (Ref: K133382) that combines a
cognitive test (continuous performance test; CPT) de-
signed to measure attention and impulse control with a
high-resolution motion-tracking system to measure
hyperactivity. The child/young person is seated in front
of a computer and is instructed to press a hand-held re-
sponder button each time a pre-designated infrequent
target stimulus appears on-screen, and to withhold the
response to all other stimuli. These features of QbTest
measure sustained and selective attention (target detec-
tion over 600 trials), and impulsivity (failure to withhold
the response to a non-target). Simultaneously, an infra-
red camera tracks the movement of a marker attached
to a headband worn during the test, to measure activity.
There is a substantial literature in cognitive psychology/
psychiatry indicating that the CPT is sensitive to inatten-
tion and impulsivity and that the addition of the activity
measure further improves sensitivity to ADHD [6]. The
test provides a summary score relevant to each symptom
domain (inattention, hyperactivity, impulsivity) with ref-
erence to a large age- and gender-stratified normative
database (Ulberstad, unpublished). The available data on
QbTest has shown good psychometric characteristics.
Qbtech report data of 85% sensitivity and 92% specificity
of classification [7]. Reh et al. [8] investigated the factor
structure, concurrent and discriminant validity of the
QbTest and found the activity measure to correlate with
hyperactivity ratings provided by teachers. Additionally,
research has shown that the activity measure can also
identify intermediate levels of impairment in ADHD sib-
lings [9]. Although the researchers point out the need
for additional research on the validity of the test, they
also found concurrent validity for the three factors (at-
tention, impulsivity and activity) [8, 9]. QbTest has also
been shown to be able to aid differentiation of ADHD
from other diagnoses in children [10] and adults [11].
Research has also indicated the QbTest is a valid meas-
ure of treatment outcome [12] and effective in measur-
ing the effects of ADHD medication [13, 14]. Audit data
also suggest that QbTest may reduce the number of as-
sessments required to reach a diagnosis [5]. However, to
the best of our knowledge, there is no published re-
search on healthcare professionals’ (HCPs) or families’
opinions on the use of objective computerised measures
to aid ADHD practice.
The ‘Assessing QbTest Utility in ADHD-Trial’
(AQUA-Trial [2]) is a randomised controlled trial
(RCT) which aims to determine whether adding the
QbTest to standard asse ssment procedures can accel-
erate time to diagnosis (whilst not compromising
diagnostic accuracy) when compared to assessment as
usual (assessment without the QbTest report). As a
secondary aim the trial also investigates whether the
QbTest can improve medication titration. A further
aim of the trial is to explore the attitudes of HCPs
and families towards QbTest. This will elucidate
potential barriers and facilitators to its use and ex-
plore stakeholders’ perspectives as to whether QbTest is
considered a valuable tool that should be implemented in
routine clinical settings. The protocol of the AQUA-Trial
is outlined in Hall et al. [2]. The AQUA-Trial is registered
with the ISRCTN registry (ISRCTN11727351) and clini-
caltrials.gov (NCT02209116).
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In order to assess the clinical utility of the QbTest to
aid ADHD assessment and medication management in
young people, we explored the perceptions of HCPs and
families (parents and young people) who participated in
the AQUA-Trial. There is a noticeable absence of quali-
tative data on the use of CPTs and other objective/com-
puterised assessments of ADHD in the literature;
however, this information is vital to inform future re-
search trials, pathways and clinical guidelines that are
designed to suit the needs of stakeholders. The aim of
this study was to explore these opinions using qualitative
data and a larger sample of survey data to cross-validate
findings.
Methods
Qualitative interviews
Participants
Participants in the AQUA-Trial were recruited from
ten sites across nine National Health Service (NHS)
Trusts in the United Kingdom. Collectively, the sites
combine Child and Adolescent Mental Health Service
(CAMHS) and Community Paediatric services. The
clinical lead for the trial at each of the ten sites was
invited to interview about their experience of the
QbTest and being part of the AQUA-Trial. The sites
were dispersed across the north, south, east and west
of England and Northern Ireland. A random selection
of parents and young people who had participated in
the trial was also invited to interview. All participants
were approached over the phone or via email by a re-
searcher, written consent was obtained as part of trial
participation. Ethical approval was granted by NRES
Committee West Midlands – Coventry and Warwick
and Research and Development Department of each
respective NHS Trust.
Healthcare professionals (HCPs) Ten out of the 10
(100%) HCP leads (one per site) that participated in
the trial agreed to be interviewed. The characteristics
of the sample are displayed in Table 1. Five HCPs
were already using QbTest as part of their clinical
practice prior to the trial; five were introduced to
QbTest as part of trial participation.
Two families per site were randomly selected for
interview. Altogether, 38 families were invited to
interview. Eighteen (47%) of those selected declined
to participate. Refusing families were replaced with
the next family until two families from each site were
enrolled for interviews, totalling 20 participants (53%
response rate of those invited to interview; 7.5% of
the total sample [n = 267] recruited into the AQUA-
Trial). The characteristics of the sample are displayed
in Table 2. In each case, the main care-giver was the
primary interviewee; however, where possible the
young person was encouraged to participate in the inter-
view with their parent. Six young people co-participated
in the interview. Two families were interviewed from each
site. All young people had been referred for an ADHD
assessment and were in the intervention arm of the trial
(received the QbTest report).
Table 1 Clinician characteristics (N = 10)
Clinician details Response (%)
Gender (Female) 8/10 (80)
Profession
Consultant Paediatrician 4/10 (40)
Consultant Psychiatrist 4/10 (40)
Nurse Specialist 2/10 (20)
Experience of ADHD Range: 8–25 years
Mean: 17 years (SD = 6.5)
Experience of QbTest Mode: 50+ tests (70%)
Range: 25 - > over 200 tests
Current methods used to diagnose ADHD:
Developmental history 10/10 (100)
Rating scales 10/10 (100)
School observation 5/10 (50)
QbTest 5/10 (50)
Current methods to manage medication:
Clinical opinion 10/10 (100)
Rating scales 4/10 (40)
QbTest 2/10 (20)
Note. Current methods to diagnose/medicate was pre-trial participation. Note.
Percentage provided in parentheses
Table 2 Family characteristics
Interview sample
n = 20 (%)
Survey sample
n = 76 (%)
Child gender (Male) 15/20 (75) 60/76 (79)
Child age M= 10.7 years
(SD = 2.9)
Range = 9–18 years
M = 10.2 years
(SD = 2.9)
Range = 7–18 years
Confirmed primary diagnosis
ADHD 11/20 (55) 35/76 (46)
Not ADHD 5/20 (25) 11/76 (14)
Unconfirmed 5/20 (25) 30/76 (39)
Co-morbidities with ADHD
Autism Spectrum Disorder 1/20 (5) 4/76 (5)
Conduct Disorder and
Oppositional Defiance
Disorder
0/20 (0) 3/76 (4)
Tourette’s/Tics 1/20 (5) 1/76 (1)
Attachment Disorder 0/20 (0) 1/76 (1)
Learning Difficulties 0/20 (0) 2/76 (3)
Anxiety and Depression 0/20 (0) 1/76 (1)
Note. Percentage provided in parentheses
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Procedure
Prior to the interviews commencing, all participants had
read an information sheet and signed a consent form.
All interviews were conducted by a trained female re-
searcher on the trial (CLH (PhD), GW (BSc), HC (MSc)
& HB (BSc)) and recorded on a Dictaphone to aid subse-
quent transcription. Interviews took place individually
with each participant over the telephone. Participants
had received some limited contact with the members of
the research team as part of the trial (e.g. questionnaire
completion and follow up reminders) and were informed
that they were being interviewed to gain their opinion
on the QbTest.
The interviews were semi-structured and guided by
separate interview schedules for each participant group
(HCP or families), the interview schedule was adapted
for the young person. Interview schedules and survey
questions were formulated prior to the main trial by the
research team. The views of parents of children with
ADHD, clinicians and an implementation expert was
sought on draft documents prior to data collection and
questions amended accordingly following their feedback.
The interview schedules were amended where necessary
throughout the trial to reflect informal feedback received
from participants regarding their experience of the trial.
By utilising a semi-structured approach, the researcher
was able to ask additional questions based on the inter-
viewees’ responses. Questions for discussion included par-
ticipant’s experience of participating in the trial, their
opinion on QbTest clinical utility, issues with current
ADHD practice (HCPs only) and the future use of the
QbTest. A series of prompts were generated for each
question to aid discussion if required. Interviews ranged
from approximately 20–60 min in length. Presented
quotes are reflective of the views of multiple responders
providing similar statements unless otherwise specified.
Analysis
Audio recordings were anonymised and transcribed verba-
tim. Transcripts were first thematically analysed by CLH
(PhD), following the guidelines of Braun and Clarke [15]
using an inductive, reflexive approach. Each coding unit
was coded exclusively into just one category rather than
multiple categories to create well defined coding categor-
ies [16]. To ensure validity and reliability of data interpret-
ation, the transcripts were then second coded by another
researcher (AZV, (PhD)). Overall themes were largely con-
sistent between coders, where contradictory coding was
apparent, the coders resolved this through discussion
until consensus was reached. The coders’ epistemol-
ogy was that of an essentialist/realist paradigm [15],
which sought to understand the opinions of QbTest
through the words of the participants, as opposed to
the researchers’ co-created meaning.
Quantitative survey
Procedure
All participants and HCPs in the trial were invited to
participate in an online survey hosted by www.survey
monkey.com. The HCP survey questions were centred
on how best to administer the QbTest, understanding
the results and communicating with families. Families in
the intervention arm of the trial were also invited to par-
ticipate. Families in the control arm were not inter-
viewed on their perceptions of QbTest as they did not
receive the QbTest report. The parent/young person sur-
vey asked questions pertaining to the utility of the
QbTest in understanding symptoms and diagnostic deci-
sions and the experience of completing the test. Data
were collected from May 2015-May 2016 and down-
loaded from the website at the end of the study. Descrip-
tive statistics were used.
Respondents
The HCP survey was sent to each participating site and
was completed by the same HCP (100% response rate)
that participated in the qualitative interview (see Table 1).
The survey was sent to all 132 families in the interven-
tion arm of the trial, of which 76 (58%) responded (see
Table 2 for sample characteristics). In each case, the sur-
vey was addressed to the primary caregiver and it was
requested that the survey was completed by the parent
and young person together (where possible). There was
no difference in age (t-test p > .05) or gender (chi-square
p > .05) of the young person between respondents in the
survey and the rest of the sample. However, there was a
significant difference in diagnosis (ADHD confirmed,
excluded, unconfirmed; chi-square p < .05), with propor-
tionately less people receiving an unconfirmed and
ADHD confirmed diagnosis in the survey sample than
the whole trial sample.
Results and discussion
Three salient themes emerged from the qualitative inter-
views, relating to the clinical validity of the QbTest, the
use of the QbTest in communication and the role of the
QbTest in the ADHD care pathway. A summary of
themes and associated sub-themes is provided in Table 3.
The findings of the qualitative interviews were supported
by the survey data which are summarised in Table 4
(HCPs’ responses) and Table 5 (families’ responses).
Theme 1 – clinical validity of QbTest
Objectivity
HCPs and families commented on the perceived validity
of the QbTest. Of particular importance to both groups
was that the QbTest report provided an objective,
observable measure of symptoms. Given the current reli-
ance on subjective approaches to diagnose ADHD [2, 6]
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it appears that clinicians and families alike would
welcome a more objective measure.
“I think to be able to see something, it’s that black and
whiteness of it, to look at it and go yeah I can see that”
(Parent 8).
HCPs noted that the objectivity of the QbTest report
encouraged them to feel more confident in their deci-
sion making.
“I would move to the diagnosis more confidently and
more quickly having evidence that something was
wrong, you know objective evidence. …reduced the
amount of the anxiety of uncertainty” (HCP 1).
The QbTest was also seen as a clinically valid tool to
objectively assess medication effects. All clinicians re-
ported that the QbTest was helpful to evaluate treatment
effects and 39% of families surveyed felt that it helped
them to understand the decisions on medication. The
uncertainty reflected by families may be because not all
participants commenced medication during the trial
(approximately 75% not medicated) and parents
responded ‘neither agree/disagree’ or ‘strongly disagree/
disagree’ when in fact they had not been prescribed
medication (see also Tables 4 and 5). HCPs reported that
their increased confidence in their diagnosis often led to
speedier initiation of medication.
“I think that I was probably quicker to agree to initi-
ation of medication when I was able to do the QbTest, I
think it probably gave parents maybe more confidence”
(HCP 4).
A thought shared by families during interviews:
“It’s a big decision to allow your children to have these
drugs, as it were. So, again, seeing those results made
me more confident that yes the medication would help
him” (Parent 17).
Understanding symptoms
All clinicians felt that the QbTest helped them to under-
stand symptoms (see Table 4), which was particularly
valuable in complex cases. In contrast, only approxi-
mately half of the survey families also felt it helped them
understand their child symptoms better (see also
Table 5). Further detailed analysis from the qualitative
interviews showed that whereas some families felt the
clinician had discussed the report fully with them, others
did not (see Theme 2 – communication). In instances
where parents felt it had helped them understand their
child symptoms and behaviours, parents sometimes re-
ported an improved parent/child relationship.
“I only see what he’s like at home so it was nice to see
what he has done [in the QbTest] to help me understand
it” (Parent 3).
In general, HCPs felt the QbTest was accurate.
However, some noted that, at times, the test contra-
dicted their clinical opinion. HCPs reported false neg-
atives occurring when they felt the child was highly
motivated to do well in the task (i.e., they enjoyed
computer tasks or did not want a diagnosis), and false
positives in the cases of children who had experi-
enced trauma.
“A couple of cases where the Conners’ [questionnaire]
and the clinical observation was ADHD, but the Qb Test
wasn’t. Mainly in girls of a certain age group and I also
Table 3 Summary of themes
Main theme Sub-themes
Clinical validity of the QbTest Objectivity
Understanding symptoms
Further evidence
Communication and the QbTest Communication between stakeholders
Effects of medication
The QbTest in the care pathway Time to diagnosis
Barriers and facilitators (time and cost,
staffing and resources, training and
practice)
Placement in pathway
Table 4 HCPs opinion on the clinical utility of the QbTest (N = 10)
Strongly agree/
agree (%)
Neither agree/
disagree (%)
Strongly disagree/
disagree (%)
Helps me understand patient symptoms 10/10 (100) 0/10 (0) 0/10 (0)
Improves patient communication 10/10 (100) 0/10 (0) 0/10 (0)
Makes it easier to explain why they do or do not have ADHD 10/10 (100) 0/10 (0) 0/10 (0)
Is not a good use of patient time 0/10 (0) 0/10 (0) 100/10 (10)
Easily incorporated into assessment clinics 10/10 (100) 0/10 (0) 0/10 (0)
Should be used routinely as part of assessment 7/10 (70) 3/10 (30) 0/10 (0)
Should be reserved for cases of diagnostic uncertainty 3/10 (30) 1/10 (10) 6/10 (60)
Best administered by HCA (or equivalent) 6/10 (60) 3/10 (30) 1/10 (10)
Best administered prior to clinicians first contact with the child 6/10 (60) 2/10 (20) 2/10 (20)
Helpful to evaluate treatment effects 10/10 (100) 0/10 (0) 0/10 (0)
Note. HCA = Healthcare Assistant. Percentage provided in parentheses
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know these girls …and they try their best and they don’t
want a diagnosis” (HCP 6).
“What I would call traumatised children …they will
invariably pop up on a Qb test as looking like ADHD”
(HCP 3).
In line with this, some interviewed families commen-
ted that a QbTest alone was not in depth enough to pro-
vide a diagnosis, and should be used in conjunction with
other measures.
“I just think there should be more, more than that to
diagnose them if you know what I mean?” (Parent 1).
This supports the British Association for Psycho-
pharmacology (BAP, [17]) guidelines that one test alone
should never be used to diagnose ADHD and the FDA
approval for QbTest not as a ‘stand-alone’ test; a point
that was also supported by our HCPs.
“We all know that they have their limitations. They are
not perfect and they never should be the only element –
but they have a place” (HCP 9).
Some HCPs commented that it was important to
observe the test in order to assess the validity of the re-
sults. Qbtech advocate that a trained professional is
present at all times during the test and that any note-
worthy behaviours or disturbances are recorded on an
observation form.
“If you’re not aware of what’s actually happening at
that time, then I think it might be difficult… the actual
observation, what’s happening during that time, is very
important” (HCP 2).
As ADHD is frequently co-morbid with other disor-
ders, this often further complicates the clinical picture
and makes interpreting reports or scales more difficult.
HCPs differed as to whether they felt QbTest was useful
in understanding co-morbidities or made a differential
diagnosis more complex. It appeared that HCPs with
greater experience of QbTest (those using QbTest prior
to the AQUA-Trial) were more positive in its ability to
help with co-morbidities than those with less experience.
“The reports were more complex to understand and
thus required as much clinical scrutiny as without the
test” (HCP 10).
In recognition of this impact of experience, Qbtech
offer clinical guidance to HCPs to aid their test inter-
pretation, particularly for complex cases. HCPs found
the test useful in terms of comorbidities, primarily
reporting the test aids the discrimination of Autism
Spectrum Disorder (ASD), which some describe as
producing in a different error pattern. In support of
this, a recent study in adults demonstrated adding the
QbTest to standard rating scales significantly im-
proved the differentiation of ADHD from ASD in
adults [11].
“I very often use it for children that I suspect have got
ASD comorbidity. I think it’s very clear that there’s a
group of children with just pure ADHD who do a Qb
Test in one way, and then the group that’s got some de-
gree of autism or autistic traits do it very differently, and
I think that’s really helpful” (HCP 2).
Other differential diagnoses that HCPs reported
being able to discriminate with the aid of QbTest
included anxiety (typically reporting improved per-
formance throughout the task), depression (slow
processing) and learning difficulties (problems under-
standing the test). HCPs commented that the test was
useful in differentiating ADHD subtypes. Interestingly,
there was no consensus as to which symptom domain
(attention, impulsivity or activity) was particularly
valuable, with each being cited as important by differ-
ent respondents. In line with this, a recent systematic
review suggests that a test that objectively measures
all three domains may be the most clinically useful
[6]. However, specifically, HCPs commented on the
utility of the attention measure for inattentive sub-
type girls which can be hard to diagnose, supporting
previous research that ADHD may be under-
diagnosed in girls [18, 19], several HCPs specifically
commented on the utility of this tool for measuring
attention in girls.
“It was the attention aspect of it about it really
helped, especially in girls…People don’t notice it be-
cause they are sitting there quietly, daydreaming”
(HCP 6).
Table 5 Families’ opinion on the clinical utility of the QbTest. (N = reported per question)
Strongly agree/
agree (%)
Neither agree/
disagree (%)
Strongly disagree/
disagree (%)
Helped us to understand the symptoms (n = 73) 35/73 (48) 22/73 (30) 16/73 (22)
The results were difficult to understand (n = 72) 17/72 (24) 29/72 (40) 26/72 (36)
Fully understood the purpose of the test (n = 74) 56/74 (76) 12/74 (16) 6/74 (8)
Found the test stressful (n = 74) 17/74 (23) 24/74 (32) 33/74 (45)
The QbTest was useful (n = 72) 41/72 (57) 18/72 (25) 13/72 (18)
Helped to understand how the diagnosis was made (n = 68) 31/68 (46) 23/68 (34) 14/68 (20)
Helped us to understand the decisions on medication (n = 52) 20/52 (39) 24/52 (46) 8/52 (15)
Note. Percentage provided in parentheses
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Further evidence
Overall respondents were supportive of the clinical val-
idity of the test. However, in support of Hall et al. [6],
some reported the need for more published data to sup-
port their clinical experience of the test.
“I think having more published research around the
accuracy of Qb would be helpful” (HCP 10).
Some HCPs and families also questioned the validity
of the clinical setting of the test. As such, there is need
for future research to further investigate the clinical and
ecological validity of the test.
“Perhaps bringing a child into a clinic, giving them a
nice structured environment is not typical of what hap-
pens in school” (HCP 1).
“He behaves differently at home and school to what he
would do in a clinical office sort of thing… And of
course for that twenty minutes that he was seen he was
on his best behaviour” (Parent 4).
Theme 2 – communication
Communication between stakeholders
HCPs and families particularly valued the QbTest report
to aid communication. All HCPs reported in the survey
that the QbTest helped improve patient communication,
however, approximately a quarter of families found the
results were difficult to understand (Tables 4 and 5).
HCPs valued being able to show an objective piece of
evidence that they could discuss with families, particu-
larly the comparison with the normative sample and the
easy to understand graphs plotting the child’s perform-
ance across the three symptom domains of ADHD.
Previous research has also shown that improved com-
munication between HCPs and families is one of the key
benefits of objective, graphical reports [2, 20].
“That [the graphs] is one of the key areas in terms of
feedback … it’s quite hard to put into words actually
how much of an improvement that makes, being able to
visibly show something to parents. And, actually, young
people” (HCP 3).
In particular, all HCPs valued the QbTest to explain
why they had ruled out a diagnosis of ADHD (Table 4).
HCPs reported this can be contentious, with families
often refuting this diagnostic decision. HCPs felt that be-
ing able to show the families a comparison of their
child’s performance to a normative sample, relatively free
from interpreter bias helped families accept this
decision.
“A lot of parents who previously would have probably
shouted and screamed at you for not saying their child
had ADHD will accept it if the computer is not showing
the evidence” (HCP 2).
In general, survey results showed that families fully
understood the purpose of the QbTest (Table 5) and, in
the interviews, families stated HCPs explained the
reports well, with parents commenting the reports were
easy to understand.
“He explained it as well, he didn’t just hand it over,
you know, he sort of said ‘well look, this is what this
means’…so he interpreted it for us” (Parent 14).
However, in some instances families that were inter-
viewed reported HCPs not explaining the report, or how
the report was used to inform the clinical decision mak-
ing, this is likely to be reflected in the survey findings
that only approximately half of the families felt that the
QbTest helped them to understand how the diagnosis
was made (see Table 5). As a consequence of this, some
families to felt that the decision had been made solely
on the QbTest report, or conversely, disappointed when
the HCP did not conclude a definitive diagnosis after the
child had taken the test. The survey findings indicate
that those who received a diagnosis of ADHD appeared
more likely to view the QbTest as useful and helpful for
understanding how the diagnosis was made than those
who did not receive an ADHD diagnosis. This may reflect
clinicians reporting that families are often disappointed or
unhappy when a diagnosis of ADHD is not made. HCPs
should ensure they clearly explain the findings of the
QbTest report and how this informed their clinical opin-
ion to improve families understanding of the test.
“I don’t know if she explained, it felt like the QbTest
had said it so that’s what we’re going with” (Parent 8).
Parents also reported that the QbTest helped them
communicate with their child, and in some cases also
helped the child gain more understanding and accept-
ance about their own symptoms. This supports previous
findings that computer-generated graphs plotting chil-
dren’s symptoms can improve communication for fam-
ilies accessing child mental health services [21].
“He was quite happy that he scored so highly on it! In
the sense of ‘see mum, it’s not my fault’ …there’s a rea-
son to this, it’s not just me being immature, pain in the
backside, whatever” (Parent 17).
During the interviews parents and HCPs commented
that the reports can also improve communication with
schools. Particularly in cases where there was a parent/
school conflict as to whether the child had a diagnosis of
ADHD.
“I’ve got something else to back me up with in what I
was saying … because I can obviously say its hyperactiv-
ity…but that test also its written proof, not just my
word” (Parent 11).
“And to discuss it with teachers who don’t see a prob-
lem, when you’ve given them a really detailed report
showing exactly why there is a problem” (HCP 5).
Communicating medication effect
HCPs reported the QbTest was useful for helping com-
municate the effect of medication to families, something
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that families can find difficult to judge. In support of
this, families participating in the qualitative interviews
commented that the QbTest helped them understand
the effect the medication was having, however, Table 5
shows that some survey respondents were less certain.
This may be partly explained by not all respondents
having experienced their child perform a QbTest on
medication. Previous research has identified that young
people taking ADHD medication would value a graph-
ical representation showing the effect of medication [20].
“Not everything you can see, if you do QbTests you
can actually see what they’re doing and then it’s all
printed out on paper and you can tell whether they’re
getting better” (Parent 5).
HCPs also noted that families can often have an un-
realistic expectation of the effect of medication and the
QbTest report can be particularly useful for demonstrat-
ing the ADHD behaviours are improving, and any ‘un-
desirable’ behaviour may actually be typical childhood
behaviour, or require a different intervention strategy
(such as parenting programmes).
“The medication’s working well, it’s really helpful to
have a bit more objective to say ‘look, actually this isn’t
necessarily to do with ADHD and it could be to do with
something else” (HCP 8).
In addition, HCPs commented that the report can be
used to resolve conflict and debate within families or
with schools as to the benefit or effect of medication.
“I've used it also in medication titration to evidence
where there is a clear difference on and off treatment
with acrimonious parents who can’t agree” (HCP 4).
As a result of being able to directly observe the effect
of medication, HCPs reported greater support from par-
ents on initiating and continuing medication, and
greater adherence to medication. Non-adherence to
ADHD medication is frequently reported [22–24] and
may explain suboptimal outcomes for young people with
ADHD [23, 25].
“They can see there is a difficulty there and that the
medication can improve that, I think it does really im-
prove adherence and understanding of what the difficul-
ties are for the kids more than anybody else” (HCP 1).
Theme 3 –QbTest in the care pathway
A pivotal theme that emerged from the data was the
potential role of the QbTest to streamline the care path-
way. Data from the AQUA-Trial showed that many re-
ferrals are not diagnosed within six months of their first
appointment. Delays in receiving ADHD diagnosis have
been previously reported [21] and may result in in-
creased health service and government expenditure as a
result of time off work and school to attend additional
clinic appointments. HCPs felt that QbTest could help
reduce delays in diagnosis and treatment onset, a finding
supported by a recent audit study [5]. Here, we present
key factors that should be considered in creating adding
QbTest to the ADHD care pathway.
“You can see that some people are much more
confident with early diagnosis, use different prepara-
tions, different titrations… and I think that one thing
would be just insist that it [the care pathway] incor-
porates something like a Qb, we’ve got to have a lot
more robust pathway and that wouldn’t be a bad
thing!” (HCP 4).
Time to diagnosis
Given pressures from service funders, commissioners
and providers, it is not surprising that HCPs were over-
whelmingly supportive of a quicker time to diagnosis
with fewer appointments. However, families were more
divided. Many quotes from families interviewed dis-
cussed the need for a quick decision in order to facilitate
early treatment initiation, particularly for children who
were struggling in education. Families also commented
that going through the diagnostic procedure can be
emotionally overwhelming for parents and children alike
and there was no gain in prolonging this.
“Because time’s precious in the education, you know in
your child’s education, well kids like this are missing out
all of the time” (Parent 19).
However, where many parents wanted to see an ‘effi-
cient’ service, a minority felt concerned that ‘labelling’ a
child should not be done quickly and the HCP should
spend time understanding the child over multiple
appointments.
“I just wished it were more like I say I was in and out,
just wished it were more appointments and a bit more
time” (Parent 1).
In line with this, interviews revealed families were di-
vided as to whether they wanted multiple short appoint-
ments or longer appointments with their HCP. Some
felt the QbTest was so brief it was best to be combined
with a clinician appointment to reduce visits, whereas
others felt a separate appointment allowed time to re-
flect on the results.
“No I think the separate appointment…having time to
process it and discuss it with him so he had time to
understand what it was he was going to do was good”
(Parent 8).
Barriers and facilitators
Time and Cost: One of the most frequently occurring
topics involved the time and cost balance of the QbTest
appointment. Families felt that the test was quick and as
a result felt it was time well spent. Survey data also sup-
port that the majority of respondents felt the test was
useful (Table 5).
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“No, I think it was a good use of time… And it didn’t
take long, we were in and out within half an hour”
(Parent 8).
HCPs commented that although the QbTest subsumes
its own time, given the objectivity of the measure it can
reduce the duration of the overall decision making
process, resulting in a quicker time to diagnosis.
“It has been helpful for me to shorten the diagnosis
process, although it adds one appointment, but…it
shortens the doubts…the being unsure” (HCP 9).
Furthermore, HCPs reported that families were happy
to complete the test, which added to the value of con-
ducting it. However, some HCPs commented that
although they felt the QbTest was worth the cost, they
were unsure that the health service would fund it.
“I’d like to advocate for that [QbTest as routine prac-
tice]. I’m not convinced the Trust would pay for it but I
would like it” (HCP 10).
Many felt that a commissioned service would be bene-
ficial to helping use QbTest, and that commissioners
would want to see evidence of a reduction in costs in
order to commission it.
“I think if commissioned would be ideal, because
there’s always the cost…and I think having it in NICE
[National Institute for Health and Care Excellence],
having it, approved in that way because CCGs are
very pedantic about what they will and will not fund”
(HCP 1).
Interestingly, a recent audit has shown that the
addition of the QbTest to standard practice actually
reduces the cost of ADHD assessment by 20% [5].
Specifically, some HCPs felt time/cost savings could be
made by replacing the lengthy and difficult to access
school observations with the QbTest.
“What we did was because of QbTest results, I then
stopped the school observations, so then we could con-
firm the diagnosis and go ahead with the medication”
(HCP 2).
Staffing and resources: One factor that influences the
time and cost is who administers the task. The majority
of HCPs felt the QbTest was best administered by a
trained healthcare assistant (HA) or equivalent, and then
interpreted by the clinician (see Table 4).
“Healthcare assistants are much more cost effective
compared to [clinicians] in delivering this test” (HCP 10).
Some clinics had a dedicated room for QbTest, those
that did not advocated that a QbTest room where the
equipment could be left set-up would reduce set-up time
and facilitate the routine use of the test.
“So that was really helpful was a nice room, we had it
all set up so it didn’t mean that we had to take it from
one place to, we go in, we do the Test, it means that we
are not wasting our time by setting it up and it all
worked really well” (HCP 6).
Some clinics cited difficulties with accessing internet
connections to upload and download the results to the
QbTest website; others mentioned the difficulties in lack
of access to a printer to print off the reports to discuss
with the families.
“There was a lot of IT [Information Technology] gov-
ernance issues to get it set up” (HCP 4).
“There are logistical problems that emerge around the
fact that we haven’t always got a printer to print out the
results and having it on paper is extremely helpful”
(HCP 10).
Training and practice: HCPs reported training and
multiple use of the QbTest as key facilitators to the use
of the test. Qbtech provides training to all clinicians
upon installation of the QbTest, which includes discus-
sions, demonstrations and practice tests. Qbtech clinical
advisors are available to offer additional test interpret-
ation support when required. The help and support from
their team received much praise.
“I think the training was really good …also what was
really helpful was being able to ring up when I had test
results that I wasn’t sure about … I think I would have
struggled to use it without that support” (HCP 8).
Placement in pathway
The majority of HCPs and families interviewed felt that
QbTest was best conducted prior to an initial appoint-
ment with the clinician (see also Table 4 for HCP survey
response). HCPs felt that in an ideal scenario QbTest
would form part of the work-up before they saw the
child, to enable them to have a better understanding of
the child’s symptoms at the first appointment and facili-
tate quicker decision making.
“I would then also even put a QbTest in as a precursor
to the initial consultation so that at the time you see the
child, they’ve had all the relevant questionnaires com-
pleted from home and school and a QbTest and you
could probably make a diagnosis on the first appoint-
ment” (HCP 4).
Likewise, families were also supportive of this, with one
suggesting it would be best placed in GP surgeries as part
of an initial screen before referral to specialist services.
“You could have it available at the doctors, so you
know if you’re going to your GP…to say you know we’re
not sure what’s going on here…then it makes something
available there” (Parent 16).
This idea was supported by HCPs who felt it would
enable children to have access to the most appropriate
service in a timelier manner, avoiding the lengthy and
unnecessary delays often seen in child mental health
settings.
“Actually having a more streamline service …rather
than someone sit on a waiting list for kind of eighteen
months, they finally come into you and you go ‘well this
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isn’t ADHD’ and then they go off to some other list!”
(HCP 3).
However, HCPs were divided as to whether the test
should be used on all cases as part of diagnostic assess-
ment (see also Table 4). In an ideal world, HCPs felt
using QbTest on all cases would be beneficial, due to its
objectivity, comparison to a normed sample and ability
to increase diagnostic confidence. However, within real-
world constraints, many felt that in straight-forward
cases the QbTest would not be necessary.
“Well, I would say it was financial constraints but
certainly time constraints and, do we actually need to be
spending that sort of money and that time or that per-
son delivering the tests, etcetera and reviewing the
results when it’s straightforward enough?” (HCP 5).
As discussed previously, there was unanimous agree-
ment from HCPs that QbTest was particularly useful in
complex and co-morbid cases, which was also cited as a
pivotal reason for delay in ADHD diagnosis. This sug-
gests QbTest could play a key role in facilitating diag-
nostic decisions in complex cases. HCPs also valued the
test for providing another measure of medication effect-
iveness. HCPs particularly reported the role of the test
to aid titration, often reporting that QbTest results led
to speedier titration and also stopping at a lower dose.
“But we saw the results of only being on the lowest
dose of a medication was …he’s brought his inattention
to zero…. So that actually said, ‘OK, that’s enough. I’m
not going to change it” (HCP 5).
Dissatisfaction with delays in medication initiation and
lengthy titrations has been previously reported by HCPs
and families [3, 20], as such, QbTest may prove a useful
tool to facilitate prescribing medication in this process.
Although the utility of the QbTest to monitor medica-
tion effects was unanimous in the survey, some inter-
view respondents felt that in simple cases, QbTests on
medication was not necessary and should be reserved
only for more complex cases or parental/school queries
about the effects of medication. This was partially driven
by concerns on cost and time.
“[The effects of], medication is so clear to most people
that it [QbTest] is only needed in those [cases] where
you're not sure or whether there’s lots of complexities
about the co-morbidity or the opinion” (HCP 4).
Interview data showed that families felt that having a
QbTest on medication was beneficial to assess the effect
of medication. In relation to this, some families also
commented that they felt abandoned by the service
post-diagnosis. Those that received medication reported
they should have been more closely monitored, and
those that were not medicated were unclear of what
options were available to them.
“Like I just feel like maybe my child by the doctors
and stuff has been let down a bit by not being seen and
just like he said he should have been seen really after the
medication and he hasn’t” (Parent 3).
Previous research has also demonstrated that families
report dissatisfaction with medication monitoring [3].
The QbTest may provide a key role in providing a more
robust monitoring system that encourages parents to
feel more supported. However, as previously discussed it
is important for HCPs to fully discuss the report to
ensure that families understand diagnosis and medica-
tion decisions.
General discussion
By gathering the perspectives of HCPs and families,
both through survey data and qualitative interviews, we
have obtained a unique insight into the feasibility and
acceptability of incorporating the QbTest as part of
practice in routine health service settings in the UK.
Overall, clinicians were very positive about the QbTest
in both the survey and interviews. However, although
the responses from interviewed families typically were
in agreement with clinicians, there was more hetero-
geneity found in the larger sample of families who
responded to the survey.
Our findings identify a number of advantages in using
QbTest, including the integration of an objective meas-
ure into an area which currently relies on clinician judg-
ment for diagnosis, an increase in clinician confidence in
decision making, perceived speedier diagnostic decisions
and medication initiation, improved understanding of
symptoms for both families and HCPs and improved
communication for multiple stakeholders. However, sur-
vey results showed some families did not find the test
useful in understanding symptoms. Combined with
some families reported concerns on how the test was
used to inform the clinician’s diagnostic decision, it is
clear that HCPs need to ensure they fully explain the use
of the test to the families to improve understanding. Re-
spondents were positive about the use of the QbTest in
the ADHD care pathway. However, these benefits need
to be offset by the costs of the test. HCPs voiced con-
cern that service commissioners would be unwilling to
fund a test that in itself does have an associated cost.
Interestingly, this unwillingness would be unlikely in
areas of physical healthcare. To balance this, HCPs cited
some ways to reduce costs including replacing lengthy
school observations with QbTest, using QbTest on
selected, complex cases and having the test conducted
by a HA. A potential care pathway emerged from the
findings, in which QbTest was conducted by a HA prior
to first contact with the clinician, allowing the clinician
to make speedier informed decisions and potentially
reducing the time to diagnosis. Recent audit data [5]
demonstrated a 20% cost reduction in diagnostic assess-
ments for ADHD after a Trust had implemented
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QbTest. Clearly, further research is needed and the
results from the AQUA-Trial [2] will provide further
evidence on the cost/benefit on the test.
Although families were supportive of the use of
QbTest to aid medication management there was greater
divide amongst HCPs as to its cost-effectiveness. Further
research should investigate the role of the QbTest in
monitoring. Additionally, future research could investi-
gate whether conducting the test at home or in school
may prove the most economical and ecologically valid
setting.
This is the first research that evaluates the views and
perceptions of HCPs and service-users on the feasibility
and acceptability of adding a computerised objective
measure to aid ADHD practice in routine health service
settings. The findings could be used to support the inte-
gration of other similar technological devices to aid
practice across other conditions. Our research is
strengthened by the inclusion of families and HCPs and
the multi-site nature of the research, which was con-
ducted in 9 NHS Trusts (10 sites) covering CAMHS and
Community Paediatric sites across the United Kingdom.
Additionally, our research is strengthened by our
sample characteristics including HCPs from different
professional backgrounds, with different lengths of
experience of QbTest (50% new to QbTest, 50% expe-
rienced prior to the trial) and families that had
received a confirmed ADHD diagnosis and no diagno-
sis. However, it may be that HCPs or families that
were particularly motivated or interested in objective
measures participated in the study. Furthermore, only
approximately half the families invited to participate
responded to the interview/survey, it is possible that
families who viewed the QbTest positively were more
likely to respond than those who did not. This poten-
tial response bias should be considered when asses-
sing the results. Few young people participated in the
interviews; as such the results are more reflective of
parent beliefs than young people. Additionally, our
sample size contained proportionately less people with
a confirmed ADHD diagnosis or unconfirmed diagno-
sis than the whole AQUA-Trial sample. Although we
would consider it likely that those with a confirmed diag-
nosis may view QbTest more favourably, equally those
with an unconfirmed diagnosis may have more negative
views of the test. Furthermore, the perceived benefits of
QbTest need to be supported by the results of a more
definitive randomised controlled trial investigating time/
cost savings.
Conclusions
The findings provide a valuable first insight into how
clinical staff and families view the addition of the QbTest
to aid the assessment and monitoring of ADHD. In
doing so, we specifically highlight the potential use of
the QbTest to streamline the care pathway and poten-
tially facilitate speedier, more accurate diagnosis and
earlier treatment initiation. The QbTest plays a key role
in facilitating communication between families, profes-
sionals and schools and may result in increased service
satisfaction. A number of clinical observations require
further exploration, such as the role of QbTest in differ-
entiating co-morbidities and medication adherence. We
advocate the need for definitive trial findings to support
these results and conclude that the findings from this
study strongly support the integration of QbTest in the
ADHD care pathway.
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